[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.194.83. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,455
Citations 0
Editorial
June 24, 2019

Blood Biomarkers for Use in Alzheimer Disease—Moving From “If” to “How?”

Author Affiliations
  • 1Institute for Translational Research, Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Ft Worth
JAMA Neurol. 2019;76(9):1009-1010. doi:10.1001/jamaneurol.2019.0845

Blood-based biomarkers have the potential to revolutionize clinical practice and clinical trials in Alzheimer disease (AD). However, to date, this “holy grail” opportunity has not been realized owing to a broad range of issues, including the lack of a clearly defined context of use (COU), lack of standardization of methods, and numerous failures at replication. Recently, however, a shift in the paradigm has occurred, with my colleagues and I proposing specific COUs for blood-based biomarkers along with potential paradigms for advancing from discovery to clinic and potential acceptable standards.1,2

×